ALPINE GROUP PARTNERS, LLC.

Lobbying for MALLINCKRODT · Specialty Pharmaceutical Company

Filing 2nd Quarter - Report

2nd Quarter (Apr 1 - June 30) 2025 · Missouri · House · Senate · $50,000.00 income · posted Jul 19, 2025

Lobbying activity 3

Health Issues

Reauthorization of the Pandemic All Hazards Preparedness Act, industrial base expansion Legislation related to drug pricing, drug price transparency and PBMS Implementation of the IRA, drug pricing provisions Legislation related to supply chains associated with active pharmaceutical ingredients and pharmaceuticals

Medicare/Medicaid

Issues related to the drug supply chains

Taxation/Internal Revenue Code

Tax incentives for the onshoring of APIs and essential medicines

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.